Nxera Pharma Statistics

Total Valuation

Nxera Pharma has a market cap or net worth of JPY 101.77 billion. The enterprise value is 122.31 billion.

Market Cap	101.77B
Enterprise Value	122.31B

Important Dates

The last earnings date was Friday, November 1, 2024.

Earnings Date	Nov 1, 2024
Ex-Dividend Date	n/a

Share Statistics

Nxera Pharma has 89.90 million shares outstanding. The number of shares has increased by 7.43% in one year.

Current Share Class	n/a
Shares Outstanding	89.90M
Shares Change (YoY)	+7.43%
Shares Change (QoQ)	+0.25%
Owned by Insiders (%)	8.28%
Owned by Institutions (%)	23.12%
Float	66.02M

Valuation Ratios

PE Ratio	n/a
Forward PE	40.64
PS Ratio	3.41
PB Ratio	1.50
P/TBV Ratio	n/a
P/FCF Ratio	58.42
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 46.02, with an EV/FCF ratio of 70.21.

EV / Earnings	-32.96
EV / Sales	4.18
EV / EBITDA	46.02
EV / EBIT	n/a
EV / FCF	70.21

Financial Position

The company has a current ratio of 4.01, with a Debt / Equity ratio of 1.02.

Current Ratio	4.01
Quick Ratio	3.73
Debt / Equity	1.02
Debt / EBITDA	26.11
Debt / FCF	39.84
Interest Coverage	-0.59

Financial Efficiency

Return on equity (ROE) is -5.90% and return on invested capital (ROIC) is -0.61%.

Return on Equity (ROE)	-5.90%
Return on Assets (ROA)	-0.54%
Return on Capital (ROIC)	-0.61%
Revenue Per Employee	78.70M
Profits Per Employee	-9.98M
Employee Count	350
Asset Turnover	0.19
Inventory Turnover	1.93

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -23.77% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-23.77%
50-Day Moving Average	1,216.46
200-Day Moving Average	1,454.33
Relative Strength Index (RSI)	40.16
Average Volume (20 Days)	634,420

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Nxera Pharma had revenue of JPY 29.28 billion and -3.71 billion in losses. Loss per share was -42.09.

Revenue	29.28B
Gross Profit	23.85B
Operating Income	-1.31B
Pretax Income	-5.11B
Net Income	-3.71B
EBITDA	2.66B
EBIT	-1.31B
Loss Per Share	-42.09

Full Income Statement

Balance Sheet

The company has 48.87 billion in cash and 69.41 billion in debt, giving a net cash position of -20.54 billion or -228.48 per share.

Cash & Cash Equivalents	48.87B
Total Debt	69.41B
Net Cash	-20.54B
Net Cash Per Share	-228.48
Equity (Book Value)	67.76B
Book Value Per Share	753.72
Working Capital	44.92B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 2.43 billion and capital expenditures -683.00 million, giving a free cash flow of 1.74 billion.

Operating Cash Flow	2.43B
Capital Expenditures	-683.00M
Free Cash Flow	1.74B
FCF Per Share	19.38

Full Cash Flow Statement

Margins

Gross margin is 81.46%, with operating and profit margins of -4.46% and -12.68%.

Gross Margin	81.46%
Operating Margin	-4.46%
Pretax Margin	-17.45%
Profit Margin	-12.68%
EBITDA Margin	9.08%
EBIT Margin	-4.46%
FCF Margin	5.95%

Dividends & Yields

Nxera Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-7.43%
Shareholder Yield	-7.43%
Earnings Yield	-3.72%
FCF Yield	1.71%

Stock Splits

The last stock split was on June 27, 2018. It was a forward split with a ratio of 4.

Last Split Date	Jun 27, 2018
Split Type	Forward
Split Ratio	4

Scores

Nxera Pharma has an Altman Z-Score of 1.27. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.27
Piotroski F-Score	n/a